Sarfaraz K. Niazi, PhD, comments on a poll he conducted revealing that many are still hesitant to remove clinical efficacy study requirements for biosimilars in his latest column.
While much has been written about the futility of comparative efficacy testing of biosimilars, the mindset of stakeholders that efficacy testing is a golden slate remains alive. I conducted a poll of my LinkedIn connections, with surprising results. Only 12% agreed that there is no need for efficacy testing; others considered pharmacodynamic (PD) biomarkers or differentiated the monoclonal antibodies (mAbs). This was not what I had expected. Although it is a smaller poll and may include biased participants, the divide is remarkable.
Niazi's Linkedin poll
The reasons for these results may come from the shared knowledge of statistics. In lay terms, the acceptable margin of difference must be smaller than the variability ever to fail a product; for all such testing, an arbitrary difference of 30% to 40% is accepted as “clinical judgment” while the real difference is almost close to zero. These trials can never fail, as thousands of such reports tell us. The reason for removing efficacy trials is not just to reduce the development cost by two-thirds, but to ensure no human abuse, according to the US 21CFR320.25(a)(13).
This issue becomes more significant when discussing interchangeability; why would 3 trials fail if 1 trial can never fail? The FDA has acknowledged that interchangeability does not ensure better biosimilar safety or efficacy. The only thing I can think of is the political concerns. Recently, Safe Biologics has begun a campaign to block the FDA from considering the removal of interchangeability. Their conference in collaboration with Generics and Biosimilars Initiative Journal conducted on November 30 was based on what I perceive to believe are misconceptions as those who presented their views had no qualification to question the FDA initiatives, in my opinion. This could be a political issue. We need to educate stakeholders that biosimilars are safe and should be affordable, if possible, without having an overwhelming focus on the development cost.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.